Personalized Therapies & Best Clinical Practices for Lung Cancer and Head & Neck Cancer--Update 2019

Personalized Therapies & Best Clinical Practices for Lung Cancer and Head & Neck Cancer--Update 2019 is organized by BioMedical Learning Institute (BMLI).

Target Audience:
The target audience includes both academic/hospital-based, and, also community-based/private practice oncologists, pathologists, immunologists, diagnostic radiation clinicians, radiation oncologists, surgical oncologists, fellows, cancer pharmacists, cancer nurses, Advanced Nurse Practitioners in Oncology, Oncology Physician Assistants and other allied HealthCare Practitioners (HCPs) who treat and care for all NSCLC, SCLC, and Head & Neck Cancer patients. Although some of the focus is on community-based practices, because of the very rapid pace at which all data is changing, all clinicians in all practice settings, including academia, are targeted, including research-based oncologists and all allied HCPs involved in thoracic oncology. All of these clinicians will benefit from the 20 Internet-based, archived Webinars.

Start Date:- Nov 14, 2019
End Date:- Nov 14, 2020

Accreditation:
Physicians:
The BioMedical Learning Institute designates this enduring activity for a maximum of 10 AMA PRA Category 1 Credits™.

Nurses:
The BioMedical Learning Institute designates this educational activity for 10 contact hours.

Pharmacists:
Credits: 10 hours (1 ceu)

Other:
Physician Assistants may receive a maximum of 10 hours of Category 1 credit for attending this symposium.

Overview:
The overall objective of the 20 archived Webinars for one year is to address the large number of professional and clinical Quality Performance Practice Gaps resulting from the continual integration of novel immune therapies, novel targeted therapies and chemotherapies into the numerous current, emerging and evolving monotherapy and combination therapy standards of care, for treating thoracic malignancies (SCLC, NSCLC, Head & Neck Cancer) as generated by the FDA approvals, and the NCCN, ASCO and other guidelines.

The emphasis of the 20 Webinars is on immune therapies, targeted therapies and molecular testing that are causing the greatest changes in standards of care for NSCLC, SCLC and Head & Neck Cancer, and as reported to us by the oncologists, pathologists, nurses, pharmacists and other HCPs that we interviewed are the basis of the most important professional Quality Performance Practice Gaps that learners want addressed with these 20 archived Webinars. Clearly, the exciting future for treating lung cancer and head & neck cancer has arrived and is “hear-now” with new clinical data on combinations and sequences of immune therapy and targeted therapy and chemotherapy to improve patient outcomes.

Learning Objectives:
Physician:
• Understand how to select from among all options to provide the optimal salvage therapy for patients with ES-Small Cell • Lung Cancer after initial therapy with the 2019 FDA-approved atezolizumab regimen using bevacizumab and chemotherapy.
• Understand how to select from among all options to provide the optimal therapy for treatment-naïve patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
• Compare and Contrast Molecular Testing Methodologies for Non-Small Cell Lung Cancer.
• Evaluate when to order NGS testing for treatment-naïve patients with nonsquamous or squamous NSCLC, including for those patients with EGFR mutations, ALK, ROS1 rearrangements and the newer driver mutations.
• Compare and contrast the immune and targeted therapy options for treating patients with nonsquamous or squamous • Non-Small Cell Lung Cancer in both the treatment naïve and salvage settings.
• Compare and contrast the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
• Evaluate the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
• Evaluate the large number of open clinical trials offering various combinations of immune and targeted therapies for Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Head & Neck Cancer as possible options for enrolling eligible patients to possibly improve outcome.
• Compare and contrast the increasing number of options for treating NSCLC patients with an EGFR-directed therapy across all lines of therapy.
• Compare and contrast the increasing number of options for treating NSCLC patients with an ALK-directed therapy across all lines of therapy.
• Understand how to apply the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
• Analyze the various predictive and prognostic markers including PD-L1, Tumor Mutation Burden (TMB) and smoking history for patients with nonsquamous and squamous Non-Small Cell Lung Cancer.
• Evaluate the various systemic and local therapies for Early-Stage NSCLC patients, including oligometastatic disease and the two FDA approved checkpoint inhibitors for Stage 3 NSCLC, durvalumab and pembrolizumab.
• Understand the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
• Compare and contrast the new FDA-approved and emerging immune therapies, targeted therapies and combinations with and without chemotherapy for squamous cell Head & Neck cancer.
• Evaluate the opportunities to address and improve priorities for the National Quality Strategy and Quality Improvement.

Nurse:
• Understand how to select from among all options to provide the optimal salvage therapy for patients with ES-Small Cell Lung Cancer after initial therapy with the 2019 FDA-approved atezolizumab regimen using bevacizumab and chemotherapy.
• Recall how to select from among all options to provide the optimal therapy for treatment-naïve patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
• Describe Molecular Testing Methodologies for Small Cell Lung Cancer.
• Review the NGS testing methodologies for patients with nonsquamous or squamous NSCLC, including for those patients with EGFR mutations, ALK, ROS1 rearrangements and the newer driver mutations.
• Define the immune and targeted therapy options for treating patients with nonsquamous or squamous Non-Small Cell Lung Cancer in both the treatment naïve and salvage settings.
• Identify the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
• Recall the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
• Review the large number of open clinical trials offering various combinations of immune and targeted therapies for • Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Head & Neck Cancer as possible options for enrolling eligible patients to possibly improve outcome.
• List the increasing number of options for treating NSCLC patients with an EGFR-directed therapy across all lines of therapy.
• Review the increasing number of options for treating NSCLC patients with an ALK-directed therapy across all lines of therapy.
• Describe how to apply the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
• Analyze the various predictive and prognostic markers including PD-L1, Tumor Mutation Burden (TMB) and smoking history for patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
• Evaluate the various systemic and local therapies for Early-Stage NSCLC patients, including oligometastatic disease and the two FDA approved checkpoint inhibitors for Stage 3 NSCLC, durvalumab and pembrolizumab.
• Understand the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
• Review the new FDA-approved and emerging immune therapies, targeted therapies and combinations with and without chemotherapy for squamous cell Head & Neck cancer.
• Describe the opportunities to address and improve priorities for the National Quality Strategy and Quality Improvement.

Pharmacist:
• Understand how to select from among all options to provide the optimal salvage therapy for patients with ES-Small Cell • Lung Cancer after initial therapy with the 2019 FDA-approved atezolizumab regimen using bevacizumab and chemotherapy.
• Recall how to select from among all options to provide the optimal therapy for treatment-naïve patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
• Describe Molecular Testing Methodologies for Small Cell Lung Cancer.
• Review the NGS testing methodologies for patients with nonsquamous or squamous NSCLC, including for those patients with EGFR mutations, ALK, ROS1 rearrangements and the newer driver mutations.
• Define the immune and targeted therapy options for treating patients with nonsquamous or squamous Non-Small Cell • Lung Cancer in both the treatment naïve and salvage settings.
• Identify the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
• Recall the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
• Review the large number of open clinical trials offering various combinations of immune and targeted therapies for Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Head & Neck Cancer as possible options for enrolling eligible patients to possibly improve outcome.
• List the increasing number of options for treating NSCLC patients with an EGFR-directed therapy across all lines of therapy.
• Review the increasing number of options for treating NSCLC patients with an ALK-directed therapy across all lines of therapy.
• Describe how to apply the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
• Analyze the various predictive and prognostic markers including PD-L1, Tumor Mutation Burden (TMB) and smoking history for patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
• Evaluate the various systemic and local therapies for Early-Stage NSCLC patients, including oligometastatic disease and the two FDA approved checkpoint inhibitors for Stage 3 NSCLC, durvalumab and pembrolizumab.
• Understand the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
• Review the new FDA-approved and emerging immune therapies, targeted therapies and combinations with and without chemotherapy for squamous cell Head & Neck cancer.
• Describe the opportunities to address and improve priorities for the National Quality Strategy and Quality Improvement.